First modification: 23/05/2022 – 12:08Last modification: 23/05/2022 – 12:06
–
London (AFP) – The British pharmaceutical company Astrazeneca announced on Monday that its Vaxzevria anticovid-19 vaccine was approved in a third dose for adults in the European Union (EU).
“Healthcare professionals can now use Vaxzevria as a third dose in patients who previously received doses of Vaxzevria or an EU-approved messenger RNA vaccine,” Astrazeneca said.
The European Medicines Agency gave the authorization on Monday “after a set of tests demonstrating an increase in the immune response after a third dose of Vaxzevria”, consecutive to two doses of Astrazeneca vaccine or another approved by the EU, according to a statement. on the agency site.
The vaccine created in collaboration with the University of Oxford has not been chosen by the British government for its booster campaign — it primarily proposes Pfizer and Moderna vaccines — despite being one of the first on the market in the United Kingdom, where it was the majority chosen for the first two doses.
Vaxzevria is however a possible option for people who have already received their first two doses in the UK.
© 2022 AFP
–
